AR032152A1 - Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica - Google Patents
Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceuticaInfo
- Publication number
- AR032152A1 AR032152A1 ARP010101697A ARP010101697A AR032152A1 AR 032152 A1 AR032152 A1 AR 032152A1 AR P010101697 A ARP010101697 A AR P010101697A AR P010101697 A ARP010101697 A AR P010101697A AR 032152 A1 AR032152 A1 AR 032152A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- hypertension
- manufacture
- pharmaceutical composition
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El uso de una combinacion de cuando menos dos componentes terapéuticos en combinacion seleccionados a partir del grupo que consiste en: (i) un antagonista del receptor AT1, o un antagonista del receptor AT1 combinado con un diurético, o en cada caso, una sal farmacéuticamente aceptable de los mismos, (ii) un inhibidor de HMG-Co-A reductasa o una sal farmacéuticamente aceptable del mismo, y (iii) un inhibidor de ACE o una sal farmacéuticamente aceptable del mismo; caracterizado porque es para la fabricacion de un medicamento para la prevencion, demora de progreso, o tratamiento de una enfermedad o condicion seleccionada a partir del grupo que consiste en hiperlipidemia y dislipidemia, ateroesclerosis, resistencia a la insulina y síndrome X, diabetes mellitus tipo 2, obesidad, nefropatía, insuficiencia renal, hipotiroidismo, sobrevivencia posterior a infarto al miocardio, enfermedades cardíacas coronarias, hipertension en la ancianidad, hipertension dislipidérmica familiar, y remodelacion enseguida de hipertension (efecto antiproliferativo de la combinacion), todas estas enfermedades o condiciones asociadas con o sin hipertension, para la prevencion, demora de progreso o tratamiento de embolia, disfuncion eréctil, y enfermedad vascular para la fabricacion de un medicamento, un agente terapéutico, y una composicion farmacéutica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19674300P | 2000-04-12 | 2000-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR032152A1 true AR032152A1 (es) | 2003-10-29 |
Family
ID=22726659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101697A AR032152A1 (es) | 2000-04-12 | 2001-04-10 | Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica |
Country Status (20)
Country | Link |
---|---|
US (2) | US20040023840A1 (es) |
EP (1) | EP1326604A2 (es) |
JP (1) | JP2003530342A (es) |
KR (1) | KR20020089433A (es) |
CN (2) | CN1440283A (es) |
AR (1) | AR032152A1 (es) |
AU (1) | AU2001258323A1 (es) |
BR (1) | BR0109966A (es) |
CA (1) | CA2405793A1 (es) |
CZ (1) | CZ20023381A3 (es) |
HU (1) | HUP0400475A3 (es) |
IL (1) | IL152079A0 (es) |
MX (1) | MXPA02010090A (es) |
NO (1) | NO20024921L (es) |
PE (1) | PE20020229A1 (es) |
PL (1) | PL365696A1 (es) |
RU (1) | RU2298418C2 (es) |
SK (1) | SK14642002A3 (es) |
WO (1) | WO2001076573A2 (es) |
ZA (1) | ZA200208203B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
RU2333757C2 (ru) * | 2000-06-22 | 2008-09-20 | Новартис Аг | Фармацевтические композиции |
US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
ATE511395T1 (de) | 2001-04-19 | 2011-06-15 | Kowa Co | Mittel zur behandlung von glomerulopathie |
US7413751B2 (en) | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
AU2002364381A1 (en) * | 2001-11-23 | 2003-06-10 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
CN100438911C (zh) * | 2002-12-27 | 2008-12-03 | 武田药品工业株式会社 | 体重增加抑制剂 |
US8293751B2 (en) | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
EP1818056A1 (de) * | 2003-01-16 | 2007-08-15 | Boehringer Ingelheim International Gmbh | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
EP1618893A4 (en) * | 2003-04-28 | 2009-08-12 | Sankyo Co | MEANS FOR INCREASING SUGAR CAPACITY |
US9345671B2 (en) | 2003-04-28 | 2016-05-24 | Daiichi Sankyo Company, Limited | Adiponectin production enhancer |
WO2005007658A2 (en) | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
AU2008201290B2 (en) * | 2003-09-26 | 2010-12-09 | Astrazeneca Uk Limited | Therapeutic treatment |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
US20070275996A1 (en) * | 2003-12-16 | 2007-11-29 | Michele Bortolini | Use of Statins For The Treatment Of Metabolic Syndrome |
DE602005025755D1 (de) * | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
JPWO2006046528A1 (ja) * | 2004-10-29 | 2008-05-22 | 興和株式会社 | 糸球体疾患治療剤 |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
US8685952B2 (en) | 2006-01-31 | 2014-04-01 | Kowa Co., Ltd. | Method for the treatment of diabetes |
JP5101306B2 (ja) * | 2006-01-31 | 2012-12-19 | 興和株式会社 | 糖尿病治療剤 |
FR2911279B1 (fr) * | 2007-01-11 | 2009-03-06 | Servier Lab | Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale |
GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
BR112013008100A2 (pt) | 2010-09-22 | 2016-08-09 | Arena Pharm Inc | "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles." |
RU2505297C1 (ru) * | 2012-11-21 | 2014-01-27 | Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") | Средство для медикаментозной коррекции нарушений нитроксидергической системы |
EP2996951B1 (en) * | 2013-05-13 | 2017-07-26 | Macro Plastics, Inc. | Shipping container comprising a safety catch |
BR102013028883A2 (pt) * | 2013-11-08 | 2015-10-06 | Hypermarcas S A | forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica |
MD4412C1 (ro) * | 2014-08-29 | 2016-11-30 | Алёна ДУРНЯ | Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă |
CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
MX2017016530A (es) | 2015-06-22 | 2018-03-12 | Arena Pharm Inc | Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1). |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
EA034975B1 (ru) * | 2018-03-13 | 2020-04-13 | Владимир Александрович Горшков-Кантакузен | Способ лечения лабильной и пароксизмальной гипертензии |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981470A (en) * | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
CA2214143A1 (en) * | 1995-04-07 | 1996-10-10 | Marc De Gasparo | Combination compositions containing benazepril or benazeprilat and valsartan |
AU716519B2 (en) * | 1995-06-30 | 2000-02-24 | Laboratoires Merck Sharp & Dohme - Chibret Snc | Method of treating renal disease using an ace inhibitor and an A II antagonist |
ATE239723T1 (de) * | 1996-03-29 | 2003-05-15 | Smithkline Beecham Corp | Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung |
DK0930076T3 (da) * | 1996-07-15 | 2005-01-31 | Sankyo Co | Farmaceutiske præparater omfattende CS-866 og insulinresistensforbedrende midler og deres anvendelse i behandlingen af arteriosclerose og xanthom |
-
2001
- 2001-04-10 CZ CZ20023381A patent/CZ20023381A3/cs unknown
- 2001-04-10 RU RU2002129558/15A patent/RU2298418C2/ru not_active IP Right Cessation
- 2001-04-10 CA CA002405793A patent/CA2405793A1/en not_active Abandoned
- 2001-04-10 KR KR1020027013336A patent/KR20020089433A/ko not_active Application Discontinuation
- 2001-04-10 WO PCT/EP2001/004115 patent/WO2001076573A2/en active Application Filing
- 2001-04-10 MX MXPA02010090A patent/MXPA02010090A/es active IP Right Grant
- 2001-04-10 BR BR0109966-3A patent/BR0109966A/pt not_active IP Right Cessation
- 2001-04-10 IL IL15207901A patent/IL152079A0/xx unknown
- 2001-04-10 AU AU2001258323A patent/AU2001258323A1/en not_active Abandoned
- 2001-04-10 PE PE2001000327A patent/PE20020229A1/es not_active Application Discontinuation
- 2001-04-10 PL PL01365696A patent/PL365696A1/xx not_active Application Discontinuation
- 2001-04-10 CN CN01807919A patent/CN1440283A/zh active Pending
- 2001-04-10 CN CNA2004101012182A patent/CN1651087A/zh active Pending
- 2001-04-10 JP JP2001574091A patent/JP2003530342A/ja active Pending
- 2001-04-10 AR ARP010101697A patent/AR032152A1/es not_active Application Discontinuation
- 2001-04-10 US US10/257,559 patent/US20040023840A1/en not_active Abandoned
- 2001-04-10 SK SK1464-2002A patent/SK14642002A3/sk unknown
- 2001-04-10 EP EP01931583A patent/EP1326604A2/en not_active Withdrawn
- 2001-04-10 HU HU0400475A patent/HUP0400475A3/hu unknown
-
2002
- 2002-10-11 ZA ZA200208203A patent/ZA200208203B/en unknown
- 2002-10-11 NO NO20024921A patent/NO20024921L/no not_active Application Discontinuation
-
2006
- 2006-10-31 US US11/590,215 patent/US20070105894A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HUP0400475A2 (hu) | 2004-06-28 |
IL152079A0 (en) | 2003-05-29 |
CZ20023381A3 (cs) | 2003-02-12 |
US20040023840A1 (en) | 2004-02-05 |
MXPA02010090A (es) | 2003-02-12 |
EP1326604A2 (en) | 2003-07-16 |
WO2001076573A2 (en) | 2001-10-18 |
SK14642002A3 (sk) | 2003-05-02 |
NO20024921L (no) | 2002-11-07 |
PL365696A1 (en) | 2005-01-10 |
BR0109966A (pt) | 2003-08-05 |
JP2003530342A (ja) | 2003-10-14 |
AU2001258323A1 (en) | 2001-10-23 |
CN1651087A (zh) | 2005-08-10 |
KR20020089433A (ko) | 2002-11-29 |
PE20020229A1 (es) | 2002-04-11 |
RU2298418C2 (ru) | 2007-05-10 |
CN1440283A (zh) | 2003-09-03 |
HUP0400475A3 (en) | 2006-02-28 |
ZA200208203B (en) | 2003-11-07 |
CA2405793A1 (en) | 2001-10-18 |
WO2001076573A3 (en) | 2003-04-17 |
US20070105894A1 (en) | 2007-05-10 |
NO20024921D0 (no) | 2002-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR032152A1 (es) | Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica | |
EP0741567B1 (en) | Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds | |
JP2019112409A (ja) | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 | |
UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
AR022085A1 (es) | Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida | |
KR20070072502A (ko) | 관절 류머티즘의 예방 및/또는 치료약 | |
AR018582A1 (es) | Forma de dosificacion en tableta para administrar un antagonista de los receptores de los leucotrienos y su uso en la preparacion de medicamentos | |
EA200300183A1 (ru) | Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции | |
RU2002105377A (ru) | Ксенон-антагонист nmda | |
AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
ES2525931T3 (es) | Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal | |
Hsu et al. | Pharmacotherapy for obesity: past, present and future | |
RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
ES2840079T3 (es) | Composición farmacéutica para el tratamiento de la esteatosis hepática no alcohólica | |
JP2006515299A5 (es) | ||
RU2005122403A (ru) | Композиции нестероидных противовоспалительных лекарственных средств, противозастойных средств и антигистаминов | |
RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
Gaudilliere et al. | To market, to market—2000 | |
US6610750B1 (en) | Treatment of osteoarthritis | |
BRPI0517983A (pt) | uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular | |
AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
US20230277523A1 (en) | Methods for inhibiting phosphate transport |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |